Abstract
Background
(±)3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is a recreational drug and brain serotonin (5-HT) neurotoxin. Under certain conditions, MDMA can also damage brain dopamine (DA) neurons, at least in rodents. Human MDMA users have been found to have reduced brain 5-HT transporter (SERT) density and cognitive deficits, although it is not known whether these are related. This study sought to determine whether MDMA users who take closely spaced sequential doses, which engender high plasma MDMA concentrations, develop DA transporter (DAT) deficits, in addition to SERT deficits, and whether there is a relationship between transporter binding and cognitive performance.
Materials and methods
Sixteen abstinent MDMA users with a history of using sequential MDMA doses (two or more doses over a 3- to 12-h period) and 16 age-, gender-, and education-matched controls participated. Subjects underwent positron emission tomography with the DAT and SERT radioligands, [11C]WIN 35,428 and [11C]DASB, respectively. Subjects also underwent formal neuropsychiatric testing.
Results
MDMA users had reductions in SERT binding in multiple brain regions but no reductions in striatal DAT binding. Memory performance in the aggregate subject population was correlated with SERT binding in the dorsolateral prefrontal cortex, orbitofrontal cortex, and parietal cortex, brain regions implicated in memory function. Prior exposure to MDMA significantly diminished the strength of this relationship.
Conclusions
Use of sequential MDMA doses is associated with lasting decreases in brain SERT, but not DAT. Memory performance is associated with SERT binding in brain regions involved in memory function. Prior MDMA exposure appears to disrupt this relationship. These data are the first to directly relate memory performance to brain SERT density.
Similar content being viewed by others
References
Berg EA (1948) A simple objective technique for measuring flexibility in thinking. J Gen Psych 39:15–22
Bhattachary S, Powell JH (2001) Recreational use of 3,4 methylenedioxymethamphetamine (MDMA) or ‘ecstasy’: evidence for cognitive impairment. Psychol Med 31:647–658
Bolla KI, McCann UD, Ricaurte GA (1998) Impaired memory function in abstinent MDMA (“ecstasy”) users. Neurology 51:1532–1537
Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of “ecstasy” use on serotonin transporters of the brain investigated by PET. J Nucl Med 44:375–384
Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M (2004) A voxel-based PET investigation of the long-term effects of “ecstasy” consumption on brain serotonin transporters. Am J Psychiatry 161:1181–1189
Chu T, Kumagai Y, DiStefano EW, Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789–796
Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338–345
Dafters RI, Hoshi R, Talbot AC (2004) Contribution of cannabis and MDMA (“ecstasy”) to cognitive changes in long-term polydrug users. Psychopharmacology (Berl) 173:405–410
Dannals R, Neumeyer J, Milius R, Ravert H, Wilson A, Wagner H (1993) Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2b-carbomethoxy-3b-(4-fluorophenyl)-[N-11C-methyl]tropane ([11C]WIN-35,428). J Label Compd Radiopharm 33:147–153
de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J (2000) Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans. Br J Clin Pharmacol 49:104–109
Easton N, Marsden CA (2006) Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 20:194–210
El-Mallakh RS, Abraham HD (2007) MDMA (ecstasy). Ann Clin Psychiatry 19:45–52
First MB, Spitzer RL, Gibbon M, Williams JB (1997) Structured clinical interview for DSM-IV axis I disorders (SCID-I), clinician version. American Psychiatric, Arlington, VA
Fox HC, Toplis AS, Turner JJD, Parrott AC (2001) Auditory verbal learning in drug-free ecstasy polydrug users. Hum Psychopharmacol 16:613–618
Frankle WG, Slifstein M, Gunn RN, Huang Y, Hwang DR, Darr EA, Narendran R, Abi-Dargham A, Laruelle M (2006) Estimation of serotonin transporter parameters with 11C-DASB in healthy humans reproducibility and comparison of methods. J Nucl Med 47:815–826
Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H, Fimm B, Sass H (2000) Impaired cognitive impairment in drug free users of recreational ecstasy. J Neurol Neurosurg Psychiatry 68:719–725
Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 55:463–508
Heinz A, Jones DW (2000) Serotonin transporters in ecstasy users. Br J Psychiatry 176:193–195
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cerebr Blood Flow Metab 27:1533–1539
Kalechstein AD, De La Garza R 2nd, Mahoney JJ 3rd, Fantegrossi WE, Newton TF (2007) MDMA use and neurocognition: a meta-analytic review. Psychopharmacology 189:531–537
Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 60:1223–1229
Lamers CT, Bechara A, Rizzo M, Ramaekers JG (2006) Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. J Psychopharmacol 20:302–311
Laruelle M (2000) The role of model-based methods in the development of single scan techniques. Nucl Med Biol 27:637–642
Laruelle M, Baldwin RM, Mallison RT, Zea Ponce Y, Zoghbi SS, Al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL, Milius RA, Wan S, Smith EO, Roth RH, Charney DS, Hoffer PB, Innis RB (1993) SPECT imaging of dopamine and serotonin transporters with 123I beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13:295–309
Marquardt DW (1963) An algorithm for least-squares estimation of non-linear parameters. J Soc Ind Appl Math 11:431–441
McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA (“ecstasy”) on brain serotonin neurons in human beings. Lancet 352:1433–1437
McCann UD, Ricaurte GA, Molliver ME (2001) “Ecstasy” and serotonin neurotoxicity: new findings raise more questions. Arch Gen Psychiatry 58:907–908
McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30:1741–1750
McCann UD, Peterson SC, Ricaurte GA (2007) The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users. Neuropsychopharmacology 32(8):1695–706
Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, Ricaurte GA (2006) Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31:339–350
Morgan MJ, McFie L, Fleetwood LH, Robinson J (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159:294–303
Parrott AC (2005) Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol 19:71–83
Reitan RM, Wolfson D (1993) The Halstead–Reitan neuropsychological test battery: theory and clinical interpretation. Neuropsychology, Tucson, AZ
Reneman L, Booij J, Schmand B, van den Brink W, Gunning B (2000) Memory disturbances in “ecstasy” users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology 148:322–324
Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J (2001) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”): preliminary findings. Arch Gen Psychiatry 58:901–906
Rey A (1964) L’examen clinicque en psychologie. Presses Universitaires de France, Paris
Schilt T, de Win MM, Koeter M, Jager G, Korf DJ, van den Brink W, Schmand B (2007) Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry 64(6):728–736
Semple DM, Ebmeier KP, Glabus MF, O’Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users. Br J Psychiatry 175:63–69
Steele TD, McCann UD, Ricaurte GA (1994) 3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”): pharmacology and toxicology in animals and humans. Addiction 89(5):539–551
Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:643–661
Szabo Z, Scheffel U, Mathews WB, Ravert HT, Szabo K, Kraut M, Palmon S, Ricaurte GA, Dannals RF (1999) Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand. J Cereb Blood Flow Metab 19:967–981
Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA (2002) Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43:678–692
Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 167:85–96
Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20:211–225
Wechsler D (1987) Wechsler memory scale-revised: manual. Psychological, New York, NY
Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S (2000) Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 43:3103–3110
Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA (2002) Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity. J Neurochem 80:960–969
Acknowledgements
We thank Kristen Kelley and Emily Dotter for their help in the data analyses and figure preparation and appreciate the following contributions to PET imaging and image analysis: Jozsef Varga, Ph.D., for the software design and implementation of the PMT software package that was used for image registration and ROI analysis; Tomas Zober, MD, for determinations of the input functions, computer network, and database management; David Clough, CNMT, and Karen Edmonds, CNMT, for the performance of PET studies; and John Hilton for the HPLC analysis of tracer metabolites. This manuscript was supported by PHS Grants DA10217 (McCann); DA05938; DA13790, DA09487, DA017964 (Ricaurte); AA11653 (Szabo) and NCRR grant M01RR002719 (Ford).
Financial disclosure
None of the authors has a biomedical financial conflict of interest or other conflict of interest that might potentially bias this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McCann, U.D., Szabo, Z., Vranesic, M. et al. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine (“ecstasy”) users: relationship to cognitive performance. Psychopharmacology 200, 439–450 (2008). https://doi.org/10.1007/s00213-008-1218-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-008-1218-4